Biejia-Ruangan compound

Phase 3Small molecule

NNanfang Hospital, Southern Medical University

Biejia-Ruangan compound is one of 30 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaNot yet recruiting

Hepatocellular CarcinomaPhase 3

Not yet recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Biejia-Ruangan compound

NNanfang Hospital, Southern Medical University

Phase 3

2 2

Ibrance

Pfizer

Preclinical

1 3

Viread

Gilead

Preclinical

1 4

Sovaldi

Gilead

Preclinical

1 5

Cysteine Hydrochloride

Novartis

Preclinical

1 6

Hepsera

Coreg

2 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Vermox

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

N/ANot yet recruiting

Hepatocellular Carcinoma

NCT07481032

Q2 2031

Post-ApprovalNot yet recruiting

Hepatocellular Carcinoma

NCT06923176

Clinical

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study

Not yet recruiting·NNanfang Hospital, Southern Medical University·N/A·NCT07481032·1,034 enrolled

Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment

Not yet recruiting·ZZhiyun Yang·Phase 4·NCT06923176·704 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Biejia-Ruangan compound. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Biejia-Ruangan compound compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Biejia-Ruangan compound. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nanfang Hospital, Southern Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNanfang Hospital, Southern Medical University

Biejia-Ruangan compound

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2031

Trials by Indication[1]

Hepatocellular Carcinoma2 trials

References

Drug Info

Quick Facts

Related News